CAR-T Therapy for Primary central nervous system Lymphoma at Sheba Medical Center
Cosa include questo pacchetto
Procedure mediche
- Terapia con cellule CAR-T
- Esami del sangue
- Esame di biochimica del sangue
- Biopsia
- TAC
- Consultazione con un medico
- Consultazione con un oncologo
- Consultazione con un ematologo
- Consultazione con un chirurgo
- Consultazione con un neurologo
- Consultazione di un radiologo
- Emocromo completo con marcatori tumorali e proteinogramma
- Angiografia TC
- Elettrocardiogramma (ECG)
- Risonanza magnetica della testa
- Cura post-operatoria
- Esami preoperatori
- PET/TC
- Consultazione con un oncoematologo
- Servizi infermieristici 24 ore su 24
- 3 pasti al giorno dal nutrizionista
Durata
- 21 giorni in ospedale
Alloggio
Ospedalizzazione
Trasporto
Trasferimento aeroporto-clinica-aeroporto
Informazioni aggiuntive
CAR-T Therapy for Primary CNS Lymphoma at Sheba Medical Center
For patients diagnosed with Primary central nervous system Lymphoma (PCNSL), a rare and complex cancer affecting the brain and central nervous system, choosing the right treatment center is critical.
Sheba Medical Center, one of the world’s leading hospitals, offers advanced CAR-T cell therapy, providing new hope for patients with relapsed or treatment-resistant disease.
Sheba combines cutting-edge immunotherapy with deep expertise in neuro-oncology, delivering highly personalized care for even the most challenging cases.
A Faster Path to Advanced Treatment
At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality crucial for patients with aggressive CNS disease.
• Apheresis – collection of the patient’s T-cells
• Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center
• Infusion – reintroduction of modified cells designed to target lymphoma cells, including those within the central nervous system
By avoiding external laboratories, treatment can begin in approximately 10 days, significantly reducing delays and allowing faster access to life-saving therapy.
CAR-T acts as a “living therapy,” continuing to work inside the body and offering the potential for long-term disease control and remission.
All patients are treated under the leadership of Prof. Arnon Nagler, a globally recognized expert in hemato-oncology.
Proven Expertise in Complex Cases
Primary CNS lymphoma requires a highly specialized, multidisciplinary approach. At Sheba, hematologists, neuro-oncologists, neurologists, and imaging specialists work together to design the most effective treatment strategy for each patient.
CAR-T therapy offers a promising option for patients who have exhausted conventional treatments, with encouraging remission outcomes even in advanced cases.
Why Patients Choose Sheba
• Rapid access to CAR-T therapy – treatment initiation in ~10 days
• Extensive experience – leading CAR-T program in the region
• Dedicated CAR-T units – with 24/7 expert monitoring
• Multidisciplinary CNS expertise – integrated hematology and neuro-oncology care
• Full international support – medical review, travel coordination, and patient assistance
Comprehensive, Personalized Care
Each patient undergoes a full evaluation, including advanced brain imaging (MRI/CT), molecular and genetic testing, and complete medical assessment, ensuring a precise and individualized treatment plan.
Services are available in English, Russian, and Arabic, providing a smooth and supportive experience for international patients.
A Leading Center for Advanced Neuro-Oncology Care
By combining innovative CAR-T technology, in-house cell production, and multidisciplinary expertise, Sheba offers one of the most advanced treatment options for Primary CNS Lymphoma worldwide giving patients access to therapies that can extend survival and improve quality of life.
Assistenza Bookimed 24/7
- Coordinatore medico personale
- Organizzazione dei viaggi medici — prenotazione di biglietti aerei e camere d'albergo a prezzi speciali per i partner
- Tutela degli interessi dei pazienti durante il viaggio medico
Prezzo del programma
Cosa NON include questo pacchetto
Medico
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.
Com'è andata la tua esperienza?
Informazioni sulla clinica
La terapia con cellule CAR T presso lo Sheba Medical Center di Tel Aviv, Israele, può costare circa $63.100 per l'intero programma. L'ospedale è tra i primi 10 al mondo e offre questo trattamento avanzato sotto la guida del Prof. Arnon Nagler, uno specialista di spicco nel trapianto di midollo osseo.
Informazioni sul Trattamento
La terapia con cellule CAR T è un approccio innovativo per leucemia, linfoma e mieloma multiplo. Essa prevede la raccolta delle cellule T del paziente, la loro modifica genetica in laboratorio e l'infusione successiva dopo la chemioterapia. Il processo richiede 21 giorni di ricovero con possibile permanenza in terapia intensiva.
Cosa è Incluso
- Valutazione completa ($5.000-$10.000)
- Raccolta delle cellule tramite aferesi ($6.600)
- Preparazione in laboratorio delle cellule modificate ($20.000)
- Condizionamento chemioterapico ($5.000)
- Ricovero di 21 giorni ($31.500)
- Valutazione post-trattamento ($3.000-$5.000)
Preparazione e Recupero
I pazienti necessitano di biopsia del midollo osseo, scansioni PET/CT e analisi del sangue prima del trattamento. Dopo l'infusione, è previsto un monitoraggio giornaliero per la sindrome da rilascio di citochine. Il soggiorno totale raccomandato in Israele è di 4-6 settimane. Si noti che la terapia CAR-T per il mieloma è ancora sperimentale.
Lo Sheba Medical Center tratta 1,5 milioni di pazienti all'anno e fornisce assistenza multilingue. È richiesto un deposito di $50.000-$60.000 prima dell'arrivo. Contattare l'ospedale per discutere se questa terapia è adatta alla vostra condizione.
Pagamenti e Benefici
I nostri servizi sono gratuiti
Il pagamento viene effettuato direttamente presso la clinica oppure tramite bonifico sul loro conto bancario ufficiale.
Alcune cliniche possono richiedere un deposito come parte della loro politica.
Paghi comodamente a rate flessibili.
Ricevi premi per raccomandare Bookimed ai tuoi amici.